Phantom EBITDA
James DeLuca
Dental founders are systematically deceived by dashboard hallucinations and flawed PMS reporting that inflate practice valuations by 25–40% during M&A transactions. Buyers deploy forensic clinical audits, EBITDA normalization tactics, and infrastructure downgrade strategies to re-trade deals after securing exclusivity.
This book exposes the exact methodology — and builds the defense. The foundational case for abandoning third-party dashboards and building institutional-grade data audit capability yourself.
Coming April 2026
Forewords from buy-side and sell-side leaders in dental M&A. Both perspectives endorsing the same forensic methodology.
Details announced at publication.
Key Frameworks
The Six Logic Leaks
Systematic flaws in PMS reporting: Multi-Option Flaw, Trigger Point Failure, PPO Phantom, Binary Acceptance Flaw, Data Lag, Internal Inconsistency.
The Corroborating Data Matrix
Self-audited, forensic-grade revenue documentation that validates every dollar of EBITDA before a buyer examines it.
The Clinical Compliance Audit
CDT code-level forensics on D2950, D7210, D4341/D4342, D3331 — the exact codes institutional buyers target.
The Normalization Lever
How buyers adjust owner compensation, related-party transactions, and non-recurring income to restate your EBITDA downward.
The Infrastructure Downgrade
Platform asset vs. add-on asset reclassification based on data architecture quality. The difference between institutional and collections-based multiples.
Frequently Asked Questions
What is phantom EBITDA?
+
Phantom EBITDA is the portion of a dental practice's reported profitability that will not survive a buyer's Quality of Earnings audit. It includes inflated production from coding drift, unsanitized PPO write-offs, owner-dependent revenue that can't transfer, and hollow growth metrics. At a 6x multiple, every $100K in phantom EBITDA destroys $600K in enterprise value.
What are the Six Logic Leaks in PMS reporting?
+
The six systematic flaws in practice management software reporting: the Multi-Option Flaw (overstating treatment acceptance), the Trigger Point Failure (misattributing production timing), the PPO Phantom (masking true write-off impact), the Binary Acceptance Flaw (1 of 6 accepted = 100% success), the Data Lag (stale metrics driving current decisions), and Internal Inconsistency (conflicting numbers across reports).
How do institutional buyers use data to re-trade dental acquisitions?
+
Buyers deploy forensic clinical audits (CDT code compliance analysis), EBITDA normalization tactics, and infrastructure downgrade strategies after securing exclusivity. The 120-day exclusivity cage gives them complete leverage — the seller can't walk away, and the buyer's QoE team systematically reduces the validated EBITDA to justify a lower purchase price.
What is a clinical compliance audit in dental M&A?
+
A forensic analysis of CDT coding patterns at the provider level. Common targets include D2950 (core buildups), D7210 (surgical extractions), D4341/D4342 (periodontal scaling), and D3331 (retreatments). Institutional buyers use coding compliance as a lever to downgrade practice valuations by reclassifying revenue as compliance-risk-adjusted.
How do I protect my valuation from phantom EBITDA?
+
Build a Corroborating Data Matrix — self-audited, forensic-grade revenue documentation that validates every dollar of EBITDA before a buyer's team examines it. This means extracting raw data (not dashboard summaries), benchmarking against institutional standards, and sanitizing provider-level coding before going to market. This is the core of PDA's Pre-LOI engagement.
